[A21-51] Olaparib (prostate cancer) - Addendum to Commission A20-106
Last updated 04.06.2021
Commission awarded on 27.04.2021 by the Federal Joint Committee (G-BA).
Adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent
Patients for whom abiraterone or enzalutamide is the best individual choice: hint of considerable added benefit.
Patients for whom docetaxel or cabazitaxel is the best individual choice: added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.